146,400 Shares in Kyverna Therapeutics, Inc. $KYTX Bought by Maven Securities LTD

Maven Securities LTD purchased a new position in Kyverna Therapeutics, Inc. (NASDAQ:KYTX) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 146,400 shares of the company’s stock, valued at approximately $1,376,000.

Several other hedge funds have also bought and sold shares of KYTX. Bank of America Corp DE lifted its stake in Kyverna Therapeutics by 41.6% in the 4th quarter. Bank of America Corp DE now owns 21,788 shares of the company’s stock worth $81,000 after purchasing an additional 6,400 shares in the last quarter. Cubist Systematic Strategies LLC lifted its stake in Kyverna Therapeutics by 31.1% in the 1st quarter. Cubist Systematic Strategies LLC now owns 68,628 shares of the company’s stock worth $132,000 after purchasing an additional 16,267 shares in the last quarter. AQR Capital Management LLC purchased a new stake in Kyverna Therapeutics in the 1st quarter worth $137,000. Rhumbline Advisers lifted its stake in Kyverna Therapeutics by 22.0% in the 1st quarter. Rhumbline Advisers now owns 31,614 shares of the company’s stock worth $61,000 after purchasing an additional 5,694 shares in the last quarter. Finally, XTX Topco Ltd purchased a new stake in Kyverna Therapeutics in the 2nd quarter worth $107,000. Hedge funds and other institutional investors own 18.08% of the company’s stock.

Kyverna Therapeutics Price Performance

Shares of NASDAQ KYTX opened at $8.06 on Monday. The firm’s 50-day moving average price is $8.99 and its 200-day moving average price is $8.55. The company has a current ratio of 8.15, a quick ratio of 8.15 and a debt-to-equity ratio of 0.13. The stock has a market capitalization of $489.97 million, a price-to-earnings ratio of -2.46 and a beta of 1.96. Kyverna Therapeutics, Inc. has a 12-month low of $2.52 and a 12-month high of $13.67.

Kyverna Therapeutics (NASDAQ:KYTX) last announced its earnings results on Tuesday, May 12th. The company reported ($0.66) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.75) by $0.09. On average, equities research analysts anticipate that Kyverna Therapeutics, Inc. will post -2.78 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts have commented on KYTX shares. Wall Street Zen cut shares of Kyverna Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 30th. HC Wainwright reiterated a “buy” rating and issued a $25.00 price target on shares of Kyverna Therapeutics in a research note on Wednesday, June 3rd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Kyverna Therapeutics in a research note on Friday, March 27th. Finally, JPMorgan Chase & Co. decreased their price target on shares of Kyverna Therapeutics from $30.00 to $29.00 and set an “overweight” rating on the stock in a research note on Wednesday, May 13th. Five analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $30.00.

Kyverna Therapeutics Company Profile

Kyverna Therapeutics is a clinical‐stage biotechnology company dedicated to developing engineered regulatory T‐cell (Treg) therapies for the treatment of autoimmune and inflammatory diseases. Leveraging a proprietary platform for the isolation, expansion and modification of Treg cells, the company aims to restore immune homeostasis in patients by delivering antigen‐specific cell therapies that selectively target diseased tissues while minimizing systemic immunosuppression.

The company’s lead programs include an allogeneic Treg candidate in clinical development for ulcerative colitis, with additional preclinical assets focused on rheumatoid arthritis and other chronic inflammatory conditions.